Results 161 to 170 of about 6,510 (202)

Nirmatrelvir+ritonavir

Reactions Weekly
  +5 more sources

Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study

Lancet, The, 2022
Carlos Wong, Chi Ho Au, Eric Ho-Yin Lau
exaly  

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

New England Journal of Medicine, 2023
Zhujun Cao, Gui Honglian, Yuan Gao
exaly  

Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment

New England Journal of Medicine, 2022
Kalpana Gupta
exaly  

Nirmatrelvir+ritonavir/tozinameran

Reactions Weekly, 2023
openaire   +1 more source

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?

Biomedicine and Pharmacotherapy, 2023
AMIRHOSSEIN SHEIDA, Hossein Bannazadeh Baghi, Mohammad Taghizadieh   +2 more
exaly  

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

New England Journal of Medicine, 2022
Weihang Bao
exaly  

Molnupiravir/nirmatrelvir+ritonavir

Reactions Weekly, 2023
  +4 more sources

Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation

Nature Medicine, 2023
Carlos Wong, Matthew S H Chung, Chi Ho Au   +2 more
exaly  

Nirmatrelvir-Ritonavir (Paxlovid)

Canadian Journal of Health Technologies
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the ...
openaire   +1 more source